Theralase(r) closes $can 1.17 million non-brokered private placement

Toronto, on / accesswire / november 29, 2023 / theralase® technologies inc. ("theralase®" or the "company") (tsxv:tlt)(otcqb:tltff), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated photo dynamic compounds ("pdcs") for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has has successfully closed a non-brokered private placement offering ("offering") of units ("units"). on closing, the corporation issued an aggregate of 5,318,183 units at a price of $0.22 per unit for aggregate gross proceeds of approximately $can 1,170,000.
CAN Ratings Summary
CAN Quant Ranking